Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Omalizumab”

213 trials

Showing 20 of 213 results

Post-approval studies (Phase 4)Study completedNCT06869382
What this trial is testing

ICS+LABA Vs. ICS+LABA+Omalizumab: Impact on Asthma Control and Gene Expression

Who this might be right for
Asthma Patients
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation 26
Not applicableStudy completedNCT05424523
What this trial is testing

Effectiveness and Safety of Omalizumab in Children With Allergic Asthma.

Who this might be right for
Allergic Asthma
Novartis Pharmaceuticals 200
Large-scale testing (Phase 3)UnknownNCT04944602
What this trial is testing

Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous Urticaria

Who this might be right for
Chronic Spontaneous Urticaria
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. 340
Early research (Phase 1)Study completedNCT00260702
What this trial is testing

Omalizumab to Treat Hyper-IgE (Job's) Syndrome

Who this might be right for
Hyper-IgE SyndromeJob's Syndrome
National Institute of Allergy and Infectious Diseases (NIAID) 1
Large-scale testing (Phase 3)Study completedNCT04976192
What this trial is testing

Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

Who this might be right for
Chronic Urticaria
Teva Pharmaceuticals USA 608
Testing effectiveness (Phase 2)Looking for participantsNCT07059091
What this trial is testing

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

Who this might be right for
Chronic Obstructive Pulmonary Disease (COPD)Allergies
Johns Hopkins University 334
Large-scale testing (Phase 3)Study completedNCT00314574
What this trial is testing

Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)

Who this might be right for
Asthma
Genentech, Inc. 850
Large-scale testing (Phase 3)Study completedNCT02329223
What this trial is testing

Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients

Who this might be right for
Chronic Spontaneous Uriticaria
Novartis Pharmaceuticals 218
Early research (Phase 1)Study completedNCT06494345
What this trial is testing

Genolair in Two Dosage Forms (Solution and Lyophilisate) and Xolair® in Healthy Volunteers

Who this might be right for
Allergic Asthma
AO GENERIUM 180
Post-approval studies (Phase 4)Study completedNCT01922037
What this trial is testing

A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)

Who this might be right for
Asthma
Hoffmann-La Roche 806
Post-approval studies (Phase 4)Study completedNCT00691873
What this trial is testing

Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids

Who this might be right for
Asthma
University of Mississippi Medical Center 14
Large-scale testing (Phase 3)Active Not RecruitingNCT06365879
What this trial is testing

To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria

Who this might be right for
Chronic Spontaneous Urticaria
Taizhou Mabtech Pharmaceutical Co.,Ltd 392
Post-approval studies (Phase 4)Study completedNCT00472030
What this trial is testing

Efficacy and Safety of Omalizumab in Bullous Pemphigoid

Who this might be right for
Bullous Pemphigoid
University of Iowa 2
Testing effectiveness (Phase 2)Study completedNCT00434434
What this trial is testing

Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma

Who this might be right for
Allergic Asthma
Genentech, Inc. 61
Large-scale testing (Phase 3)Study completedNCT02049294
What this trial is testing

Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis

Who this might be right for
Steroid and/or Prednisone Dependent AsthmaEosinophilic Bronchitis
McMaster University 11
Post-approval studies (Phase 4)Study completedNCT00670930
What this trial is testing

Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists

Who this might be right for
Allergic Asthma
Novartis Pharmaceuticals 36
Post-approval studies (Phase 4)Study completedNCT01430403
What this trial is testing

Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations

Who this might be right for
Asthma
National Institute of Allergy and Infectious Diseases (NIAID) 478
Not applicableActive Not RecruitingNCT06771934
What this trial is testing

Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe Asthma

Who this might be right for
Allergic Asthma
Qianfoshan Hospital 60
Testing effectiveness (Phase 2)Looking for participantsNCT06934200
What this trial is testing

Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels

Who this might be right for
Food Hypersensitivity
Johns Hopkins University 32
Post-approval studies (Phase 4)Ended earlyNCT01912872
What this trial is testing

Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma

Who this might be right for
Severe IgE-mediated Asthma
Novartis Pharmaceuticals 112
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation